PALS Program for Developmental Delay
(INTACT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a program called PALS, which provides personalized coaching to help parents enhance their infants' neurodevelopment. It targets infants exposed to cannabinoids (substances from the cannabis plant) before birth. The trial examines whether monthly coaching sessions over a year can improve developmental outcomes. Ideal candidates are parents who used cannabinoids during pregnancy and have a healthy, full-term newborn without severe birth complications. Participants must have internet access and a device for video conferencing. As an unphased trial, this study offers parents a unique opportunity to contribute to research that could improve developmental support for infants exposed to cannabinoids.
Will I have to stop taking my current medications?
The trial does not specify whether you need to stop taking your current medications. However, it excludes participants who used opiates or other illicit drugs during pregnancy, so it might be important to discuss your current medications with the study team.
What prior data suggests that the PALS Program is safe for infants?
Research has shown that the PALS Program, which includes personalized coaching sessions, is based on successful methods that improve infant development. While specific safety data from clinical trials on the PALS Program is not available, it employs well-established techniques focused on training parents. These techniques are generally safe, as they do not involve medication or medical procedures. The program aims to enhance communication and interaction between parents and infants, which is considered safe. The study is in the "Not Applicable" phase, indicating it is in the early stages and is testing the program's practicality rather than focusing on safety results. Although extensive safety data may not yet be available, the program is expected to be low-risk due to its non-invasive nature.12345
Why are researchers excited about this trial?
The PALS Program is unique because it focuses on personalized coaching sessions for birthing parents to improve neurodevelopmental outcomes in infants exposed to cannabinoids. Unlike standard treatments for developmental delay, which often involve medication or generalized therapies, this program emphasizes contingent responding—a tailored approach where parents learn to interact with their infants in specific, responsive ways. Researchers are excited about this method because it has the potential to directly engage and enhance the infant-parent bond, potentially leading to significant improvements in the child's development without the need for pharmaceuticals.
What evidence suggests that the PALS Program is effective for improving neurodevelopmental outcomes in infants?
Research has shown that early intervention programs like PALS can improve brain and behavior outcomes in children, especially those born prematurely. Studies have found that early parenting programs enhance development by teaching parents how to interact with their babies in ways that support growth. The PALS Program, tested in this trial, specifically helps parents improve their babies' brain health, which is crucial for children exposed to cannabis before birth. Early interventions have proven effective in addressing developmental challenges, offering hope for better infant development. In this trial, the PALS Program guides parents through personalized coaching sessions to help these infants catch up developmentally.678910
Who Is on the Research Team?
Jessie Maxwell, MD
Principal Investigator
University of New Mexico
Leigh-Anne Cioffredi, MD
Principal Investigator
University of Vermont
Maria Barber, DO
Principal Investigator
Avera Research Institute
Are You a Good Fit for This Trial?
This trial is for birthing parent/infant pairs where the infant was exposed to cannabinoids before birth and may be at risk of developmental delays. The study will involve 20 pairs across three sites.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Study Development and Start-up
Initial phase for study development and preparation
Screening and Enrollment
Participants are screened for eligibility to participate in the trial
Intervention
Participants receive 12 monthly INTACT intervention coaching sessions
Data Organization and Analysis
Data organization, clean-up, and manuscript preparation
Follow-up
Participants are monitored for completion of the intervention and adherence
What Are the Treatments Tested in This Trial?
Interventions
- PALS Program
Trial Overview
The INTACT trial is testing a program called Play and Learn Strategies (PALS) to see if it can help improve brain development in infants who were exposed to cannabinoids in the womb.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
A novel program to train birthing parents in contingent responding with the goal of improving neurodevelopmental outcomes in infants prenatally exposed to cannabinoids. 1 personalized coaching session per month for 12 months.
Find a Clinic Near You
Who Is Running the Clinical Trial?
IDeA States Pediatric Clinical Trials Network
Lead Sponsor
University of Vermont
Collaborator
University of New Mexico
Collaborator
Avera Research Institute
Collaborator
National Institutes of Health (NIH)
Collaborator
Published Research Related to This Trial
Citations
PALS Study – LEED at UH - University of Houston
A remotely – delivered early parenting program, PAL Strategies (PALS), supports healthy brain and behavior outcomes in toddlers born prematurely.
Detection of pediatric developmental delay with machine ...
A prediction model built accordingly can be employed to screen the subjects who may develop DD before advanced and costly diagnoses are carried out.
Effectiveness of early intervention and prediction ...
In our study, fewer preterm children than full-term children exhibited improved developmental outcomes.
Family outcomes of a parent-implemented early ...
Neurodevelopmental disorders have become global public health challenges, and early interventions have been proved to be effective in mitigating the problems ...
5.
centerwatch.com
centerwatch.com/clinical-trials/listings/NCT06423664/improving-neurodevelopmental-outcomes-after-prenatal-cannabinoid-in-utero-exposureImproving Neurodevelopmental ouTcomes After Prenatal ...
The trial will enroll 20 birthing parent/infant dyads across three sites and will evaluate feasibility endpoints rather than clinical outcomes.
Neurodevelopmental delay: Case definition & guidelines for ...
Data from 2009 in Australia estimated 7.0% of children ages 0–14 years met criteria for a broader definition of disability encompassing developmental delays, ...
Pals Assessment
Scores are typically compared against normative data to determine developmental status. Patterns in the scores can indicate specific areas needing ...
8.
jneurodevdisorders.biomedcentral.com
jneurodevdisorders.biomedcentral.com/articles/10.1186/s11689-021-09393-yPre-symptomatic intervention for autism spectrum disorder ...
Evidence from preclinical trials suggest that intervention prior to the onset of ASD symptoms may yield more improved developmental outcomes, ...
Long‐Term Neurodevelopmental Outcomes of the SAFE ...
Significant improvements were observed in motor and language composite scores in the SAFE group between baseline (T1) and the 3-month follow-up ...
The protocol for a pilot feasibility trial of Improving ...
Thus, this pilot feasibility trial will focus on birthing parent interventions modeled on PALS/ePALS with the goal of improving the infant developmental ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.